Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-BEZ235—a dual PI3K/mTOR inhibitor—and RAD001—an mTOR inhibitor—in 13 en...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360787/ |